Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Hansa Biopharma AB California Sweden

Strong revenue generation in Q4 2023, including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and SpainEncouraging first results from first-in-human trial of HNSA-5487, Hansa's lead candidate from the NiceR program for repeat dosingInitiation of phase 1b trial of imlifidase as pre-treatment to Sarepta's SRP-9001 in DMD View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-provides-update-on-business-and-key-financials-ahead-of-the-jp-morgan-healthcare-conference-302027692.html